Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease.

ABSTRACT:

Background

As the patents of originator biologics are expiring, biosimilar versions are becoming available for the treatment of inflammatory bowel disease (IBD). However, published switch studies of the first infliximab biosimilar, CT-P13, have delivered ambiguous results that could be interpreted as showing a trend towards inferior effectiveness in Crohn's disease (CD) compared with ulcerative colitis (UC). The aim of this study was to investigate the effectiveness and safety of switching IBD patients from treatment with Remicade to CT-P13.

Methods

In this prospective observational cohort study, all adult IBD patients on Remicade treatment, at four hospitals, were switched to CT-P13. The primary endpoint was change in clinical disease activity at 2, 6, and 12 months after t

SUBMITTER: Bergqvist V 

PROVIDER: S-EPMC6187418 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature